Bristol-Myers Squibb brings Opdivo to a joint immuno-oncology program with Nektar’s new T cell amplifier
Six years ago, when Steve Doberstein took over as chief scientific officer at Nektar Therapeutics, he set up a new biologics research group with an eye to expanding on the biotech’s base of small molecules. The very first project they would undertake went on to become NKTR-214, a preclinical biologic that the company believes can play a role in immuno-oncology.
Today, Nektar is pulling the wraps off a deal to collaborate with Bristol-Myers Squibbs’ I/O allstars in R&D to see how their experimental drug matches up with Opdivo, one of the leaders in the first wave of checkpoint inhibition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.